Dr. Yu joined Forward Ventures in 2015 to direct its efforts to organize a cross-border program involving Asia and China, in particular. Dr. Yu’s career in biotechnology began as a scientist-entrepreneur 25 years ago, and most recently was CEO of Ansun Biopharma, which has received more than $120M from US government and private funding sources for drug development, including a ~$60M National Institutes of Health contract for development of a novel, broad spectrum influenza biological therapeutic. Ansun Biopharma has received the “Scientific American 50” award for this innovative drug. Prior to founding Ansun Biopharma, Dr. Yu was a co-founder and Executive Vice President of CFY Biomedicals, Inc., for which he has raised multiple rounds of VC financings for the Company. CFY’s lead product, ColdSol which is a common cold medicine, won the CONNECT Award for Most Innovative New Product in 2002.   Prior to CFY Biomedicals, Dr. Yu was a scientific co-founder of ItherX Pharmaceuticals for drug development against HIV, HBV, and HCV. Dr. Yu is uniquely positioned to lead Forward Venture’s China/Asia program as he is also a founding board member of BayHelix, currently one of the most influential organizations of leaders of Chinese heritage in the global life sciences and healthcare community. Dr. Yu holds a Ph.D. in Biochemistry & Molecular Biology from Indiana University School of Medicine, and received his BS and MS degrees from Fudan University. Dr. Yu was named as “Entrepreneur of 2008, We Chinese in America”

Mang (Mark) Yu, PHD

Managing Partner